Obesity 2020-Jul
The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID-19
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
Palabras clave
Abstracto
Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin-converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non-overweight counterparts.